Saltar al contenido
Merck

07-1437

Anti-PDGF-BB Antibody

from rabbit, purified by affinity chromatography

Sinónimos:

Platelet-derived growth factor B chain precursor, Platelet-derived growth factor beta polypeptide, Platelet-derived growth factor, beta polypeptide (oncogene SIS), oncogene SIS, Platelet-derived growth factor, Platelet-derived growth factor beta, Platele

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño


Acerca de este artículo

UNSPSC Code:
12352203
NACRES:
NA.41
eCl@ss:
32160702
Conjugate:
unconjugated
Clone:
polyclonal
Application:
ELISA, Neutral, WB
Citations:
5
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle

biological source

rabbit

conjugate

unconjugated

antibody form

affinity purified immunoglobulin

antibody product type

primary antibodies

clone

polyclonal

purified by

affinity chromatography

species reactivity

human

technique(s)

ELISA: suitable, neutralization: suitable, western blot: suitable

isotype

IgG

NCBI accession no.

UniProt accession no.

shipped in

dry ice

target post-translational modification

unmodified

Quality Level

Gene Information

human ... PDGFB(5155)

General description

28 kDa
Platelet-Derived Growth Factor (PDGF) is a dimer of A (17 kDa) and B (14 kDa) chains (AA, AB, or BB). Its receptors are transmembrane receptor tyrosine kinases, PDGF Receptors type A and B. The type A PDGF receptor binds all three PDGFs with high affinity, whereas the type B PDGF receptor is selective for PDGF-BB. PDGF signals as a growth and survival factor, as it is a potent activator of the PI3 Kinase pathway. PDGF signaling appears to play an essential role in the development of tumors of glial origin.

Immunogen

Highly purified (>98%) recombinant human PDGF-BB

Application

Anti-PDGF-BB Antibody detects level of PDGF-BB & has been published & validated for use in WB, ELISA, NEUT.
ELISA: 0.5 μg/mL dilution of a previous lot will allow detection (in direct ELISA) of
0.2-0.4 ng/well when human PDGF-BB is used to coat the plate.

Neutralization: To yield ½ maximal inhibition (ND50) of the biological activity of hPDGF-BB (2.5
ng/mL), a concentration of 0.03-0.04 μg/mL of a previous lot of this antibody was required.

Immunohistochemistry(paraffin): Anti-IGF-1R, representative staining-pattern and morphology on ductal breast carcinoma. Tissue was pretreated with EDTA, pH 8.0 for Epitope retrieval. A previous lot of this antibody was diluted to 1:200 (RT incubation), using IHC-Select Detection with HRP-DAB.

Optimal working dilutions must be determined by the end user.
Research Category
Signaling
Research Sub Category
Growth Factors & Receptors

Biochem/physiol Actions

Reacts with human PDGF-BB.

Physical form

Affinity purified
Purified rabbit polyclonal IgG lyophilized from 0.5X PBS, pH 7.4. Reconstitute with sterile distilled water.

Preparation Note

Maintain lyophilized material desiccated below 0°C. After reconstitution maintain at -20°C in convenient undiluted aliquots for up to 6 months from date of receipt.
Handling Recommendations: Upon first thaw, and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.

Analysis Note

Routinely evaluated by Western Blot on Huvec lysates.

Western Blot Analysis:
1:500 dilution of this lot detected PDGF-BB on 10 μg of Huvec lysates.

Other Notes

Replaces: AB1487P

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

¿No encuentra el producto adecuado?  

Pruebe nuestro Herramienta de selección de productos.

Clase de almacenamiento

13 - Non Combustible Solids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Ahmed Ismaeel et al.
Biochimica et biophysica acta. Molecular basis of disease, 1868(1), 166278-166278 (2021-10-04)
The vascular pathology of peripheral artery disease (PAD) encompasses abnormal microvascular architecture and fibrosis in response to ischemia-reperfusion (I/R) cycles. We aimed to investigate the mechanisms by which pathological changes in the microvasculature direct fibrosis in the context of I/R.
Huber Lena et al.
Journal of tissue engineering, 13, 20417314221114423-20417314221114423 (2022-09-27)
Nasal septum defects can currently only be reconstructed using autologous cartilage grafts. In this study, we examine the reconstruction of septal cartilage defects in a rabbit model using porcine decellularized nasal septal cartilage (DNSC) functionalized with recombinant platelet-derived growth factor-BB
Gesine Paul et al.
The Journal of clinical investigation, 125(3), 1339-1346 (2015-02-18)
BACKGROUND. Recombinant human PDGF-BB (rhPDGF-BB) reduces Parkinsonian symptoms and increases dopamine transporter (DAT) binding in several animal models of Parkinson's disease (PD). Effects of rhPDGF-BB are the result of proliferation of ventricular wall progenitor cells and reversed by blocking mitosis.
Tianrun Liu et al.
Nature communications, 9(1), 3439-3439 (2018-08-29)
Angiogenesis is a hallmark of cancer. However, most malignant solid tumors exhibit robust resistance to current anti-angiogenic therapies that primarily target VEGF pathways. Here we report that endothelial-mesenchymal transformation induces glioblastoma (GBM) resistance to anti-angiogenic therapy by downregulating VEGFR-2 expression
Jin-Woo Lee et al.
Journal of hematology & oncology, 14(1), 148-148 (2021-09-18)
Little is known about endogenous inhibitors of angiogenic growth factors. In this study, we identified a novel endogenous anti-angiogenic factor expressed in pericytes and clarified its underlying mechanism and clinical significance. Herein, we found Kai1 knockout mice showed significantly enhanced

Número de artículo de comercio global

SKUGTIN
07-143704053252337048

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico